The drugmakers have filed alirocumab with the FDA, closing the gap between its candidate and Amgen's evolucumab.
Two new classes of medicines have shown unparalleled efficacy in oncology, but there are growing concerns about the treatments' safety.
CEO Ian Read told investors the company has cash to make a deal, but there is no urgent need.
We need to help our health systems and healthcare companies function like agile start-ups
Key trends from the latest Consumer Electronics Show through the eyes of NostaLab's John Nosta
Stop trying to sell your edgy work as a TV spot. By finding a backdoor through digital, risky work can often see the light of day, says one ad consultant.